MATRIX - Modeling Macrophages Activation Pattern in X-linked Adrenoleukodystrophy, Metachromatic Leukodystrophy and Adult Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

This study is a national, non-randomized, open-label, multi-site with minimal risk study in adult with adrenomyeloneuropathy (AMN), childhood and adult subjects with cerebral ALD (cALD), juvenile/adult metachromatic leukodystrophy (MLD) and adults with leukoencephalopathy and axonal spheroids and pigmented glia (ALSP). 49 subjects will be enrolled with one blood sample collection during one of their medical follow-up visit. This trial will evaluate the role of innate immunity to influence disease progression in X-ALD, MLD and ALSP, and if the mutations related to these leukodystrophies result in a specific immune response leading to the pathogenesis.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 1
Maximum Age: 60
Healthy Volunteers: t
View:

⁃ Boys aged between 3 and 18 years (inclusive) diagnosed with C-CALD (elevated levels of VLCFA and leukodystrophy at brain MRI)

• Boys or girls aged between 15 months and 18 years (inclusive) diagnosed with MLD (low ARSA activity and accumulation of sulfatides in urine)

• Presymptomatic boys carrying ABCD1 mutations aged between 3 and 18 years (inclusive) (PRE-ALD)

• Adult males or females aged between 18 and 60 diagnosed with MLD (low ARSA activity and accumulation of sulfatides in urine)

• Males aged between 18 and 60 years diagnosed with AMN (elevated VLCFA and clinical symptoms of AMN without leukodystrophy at brain MRI)

• Males aged between 18 and 60 years diagnosed with CALD (elevated VLCFA with leukodystrophy at brain MRI)

• Adult males or females aged between 18 and 60 years diagnosed with ALSP (CSF1R mutation and leukodystrophy at brain MRI)

• Presymptomatic patient adults (males or females) carrying CSF1R mutations (PRE-ALSP)

• Children (15 months-18 years) without neurologic disease (no obvious neurological symptoms, normal neurologic examination)

• Adults aged between 18 and 60 years without neurologic disease (no overt neurological symptoms)

• Informed consent obtained :

• from the parents or guardian for children patients and children controls;

• from subject himself for adult patients and adult controls.

Locations
Other Locations
France
AP-HP Hôpital Bicêtre
RECRUITING
Le Kremlin-bicêtre
AP-HP Hôpital La Pitié Salpêtrière
RECRUITING
Paris
Contact Information
Primary
Fanny MOCHEL
fanny.mochel@icm-institut.org
01 57 27 44 82
Backup
Christelle AUGER
christelle.auger@aphp.fr
Time Frame
Start Date: 2021-08-30
Estimated Completion Date: 2027-02
Participants
Target number of participants: 100
Treatments
affected subjects
* adult patients with adrenomyeloneuropathy/adrenoleukodystrophy~* children with adrenoleukodystrophy~* children with metachromatic leukodystrophy
control subjects
* healthy children~* heatthy adults
Sponsors
Collaborators: URC-CIC Paris Descartes Necker Cochin
Leads: Assistance Publique - Hôpitaux de Paris

This content was sourced from clinicaltrials.gov